MedPath

A randomised trial of radiotherapy alone versus three cycles of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy plus radiotherapy versus six cycles of CHOP chemotherapy plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma

Not Applicable
Completed
Conditions
on-Hodgkin's lymphoma
Cancer
Non-Hodgkin's lymphoma
Registration Number
ISRCTN55593137
Lead Sponsor
Cancer Research UK (CRUK) (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Biopsy-proven non-Hodgkin's lymphoma of any of the following histologies: International Working Formulation groups F, G and H; Kiel Classification: centroblastic B-cell, pleomorphic medium and large T-cell, immunoblastic, large cell anaplastic and high grade unclassified; Revised European-American Classification of Lymphoid Neoplasms (REAL Classification): Diffuse large B-cell, anaplastic large cell, high-grade B-cell or Mucosa-associated lymphoid tissue (MALT) type, and peripheral T-cell
2. WHO performance status 0, 1, 2
3. Aged greater than 15 years
4. No previous chemotherapy or radiotherapy 5. Normal lactic dehydrogenase (LDH)
6. Stage I, IE, II, IIE, except bulky abdominal presentation
7. No B symptoms
8. No previous malignancy, except basal cell carcinoma of the skin or cervical carcinoma stage I
9. No evidence of Human Immunodeficiency Virus (HIV) positively
10. No contraindications to protocol treatments

Exclusion Criteria

Patients with testicular, brain, gastrointestinal or skin primaries are excluded

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ot provided at time of registration
Secondary Outcome Measures
NameTimeMethod
ot provided at time of registration
© Copyright 2025. All Rights Reserved by MedPath